Revolutionizing Precision Oncology through Collaborative Proteogenomics and Data Sharing

The integration of proteomics into precision oncology presents opportunities that may transform the molecular analysis of cancer and accelerate basic and clinical cancer research. This Commentary discusses the importance of international collaboration and data sharing inspired by the Cancer Moonshot to accelerate the progress of multi-omic precision medicine-an approach that addresses the global diversity of people and of cancers.

[1]  Michael L. Gatza,et al.  Proteogenomics connects somatic mutations to signaling in breast cancer , 2016, Nature.

[2]  M. Ranson,et al.  Where next for gefitinib in patients with lung cancer? , 2006, The Lancet. Oncology.

[3]  Christopher R Kinsinger,et al.  Protein-based multiplex assays: mock presubmissions to the US Food and Drug Administration. , 2010, Clinical chemistry.

[4]  Jacob D. Jaffe,et al.  Proteogenomic mapping as a complementary method to perform genome annotation , 2004, Proteomics.

[5]  Jeffrey R. Whiteaker,et al.  Proteogenomic characterization of human colon and rectal cancer , 2014, Nature.

[6]  Francisco Cervantes,et al.  Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. , 2006, The New England journal of medicine.

[7]  Birgit Schilling,et al.  Repeatability and reproducibility in proteomic identifications by liquid chromatography-tandem mass spectrometry. , 2010, Journal of proteome research.

[8]  Christoph H Borchers,et al.  Multi-site assessment of the precision and reproducibility of multiple reaction monitoring–based measurements of proteins in plasma , 2009, Nature Biotechnology.

[9]  Pei Wang,et al.  Demonstrating the feasibility of large-scale development of standardized assays to quantify human proteins , 2013, Nature Methods.

[10]  Brendan MacLean,et al.  Bioinformatics Applications Note Gene Expression Skyline: an Open Source Document Editor for Creating and Analyzing Targeted Proteomics Experiments , 2022 .

[11]  Ronald J. Moore,et al.  Integrated Proteogenomic Characterization of Human High-Grade Serous Ovarian Cancer , 2016, Cell.

[12]  Susan E. Abbatiello,et al.  Targeted Peptide Measurements in Biology and Medicine: Best Practices for Mass Spectrometry-based Assay Development Using a Fit-for-Purpose Approach* , 2014, Molecular & Cellular Proteomics.

[13]  D. Slamon,et al.  Biological rationale for HER2/neu (c-erbB2) as a target for monoclonal antibody therapy. , 2000, Seminars in oncology.

[14]  Brendan MacLean,et al.  CPTAC Assay Portal: a repository of targeted proteomic assays , 2014, Nature Methods.

[15]  Richard D. Smith,et al.  Recommendations for mass spectrometry data quality metrics for open access data (corollary to the Amsterdam principles) , 2012, Proteomics.

[16]  Richard D Smith,et al.  Recommendations for Mass Spectrometry Data Quality Metrics for Open Access Data (Corollary to the Amsterdam Principles)* , 2011, Molecular & Cellular Proteomics.

[17]  Richard D Smith,et al.  Recommendations for mass spectrometry data quality metrics for open access data (corollary to the Amsterdam principles) , 2011, Proteomics. Clinical applications.